Alessandra Cipriano
Research Subjects
Alessandra Cipriano has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Ellie He
Imbrium Therapeutics L.P., a subsidiary of Purdue Pharma L.P. Stamford Connecticut USA
2 shared publications- Garth T. Whiteside
Discovery Research, Purdue Pharma L.P., 6 Cedar Brook Drive, Cranbury, NJ 08512, USA
2 shared publications Glen Apseloff
Ohio Clinical Trials, LLC Columbus Ohio USA
2 shared publications- Manjunath S. Shet
Imbrium Therapeutics L.P., Stamford, CT
2 shared publications Manjunath Shet
Imbrium Therapeutics L.P., a subsidiary of Purdue Pharma L.P. Stamford Connecticut USA
2 shared publicationsStephen C. Harris
Imbrium Therapeutics L.P., a subsidiary of Purdue Pharma L.P. Stamford Connecticut USA
2 shared publications
Latest Publications
- Open Access
- 23 March 2026
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 46 (3) , 297-310
Human Abuse Potential of Single Oral Doses of Sunobinop, a Novel, Highly Potent, and Selective Partial Agonist for Nociceptin/Orphanin-FQ Peptide (NOP) Receptors
Background: Sunobinop is a selective, partial agonist of the nociceptin/orphanin FQ peptide receptor and has multiple potential indications, including insomnia, bladder disorders, and alcohol use disorder. The purpose of this study was to examine the abuse potential and pharmacodynamic effects of sunobinop compared with triazolam in healthy adults with a history of nonmedical use of central nervous system drugs with depressant/sedative properties. Methods: This was a single-dose, randomized, double-blind, double-dummy, placebo-controlled and positive-controlled crossover study. Each participant received 6 treatments: sunobinop 1 mg, 6 mg, and 10 mg plus triazolam placebo, sunobinop placebo plus triazolam 0.5 mg and 1 mg, and sunobinop placebo plus triazolam placebo. The primary endpoint for the treatment phase was “at this moment” drug-liking visual analog scale (VAS) maximum effect (0 to 100). Results: Fifty participants completed the study. The mean “at this moment” drug-liking VAS scores for sunobinop 1 mg remained within the neutral range (40 to 60) with a peak score of 54.1 and comparable with placebo at all time points. In contrast, “at this moment” drug-liking VAS scores for triazolam control doses increased over time, peaking ∼2 hours following dosing at a mean score of 65.0 and 63.4 for triazolam 0.5 mg and 1.0 mg, respectively. Conclusions: Drug-liking following sunobinop at a potential therapeutic dose was not different from placebo and was significantly lower compared with triazolam at a recommended dose. In addition, its good tolerability profile suggests sunobinop may be a useful new treatment option, particularly in at-risk populations.
- 23 March 2026
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 46 (3) , 297-310
Open AccessHuman Abuse Potential of Single Oral Doses of Sunobinop, a Novel, Highly Potent, and Selective Partial Agonist for Nociceptin/Orphanin-FQ Peptide (NOP) Receptors
Background: Sunobinop is a selective, partial agonist of the nociceptin/orphanin FQ peptide receptor and has multiple potential indications, including insomnia, bladder disorders, and alcohol use disorder. The purpose of this study was to examine the abuse potential and pharmacodynamic effects of sunobinop compared with triazolam in healthy adults with a history of nonmedical use of central nervous system drugs with depressant/sedative properties. Methods: This was a single-dose, randomized, double-blind, double-dummy, placebo-controlled and positive-controlled crossover study. Each participant received 6 treatments: sunobinop 1 mg, 6 mg, and 10 mg plus triazolam placebo, sunobinop placebo plus triazolam 0.5 mg and 1 mg, and sunobinop placebo plus triazolam placebo. The primary endpoint for the treatment phase was “at this moment” drug-liking visual analog scale (VAS) maximum effect (0 to 100). Results: Fifty participants completed the study. The mean “at this moment” drug-liking VAS scores for sunobinop 1 mg remained within the neutral range (40 to 60) with a peak score of 54.1 and comparable with placebo at all time points. In contrast, “at this moment” drug-liking VAS scores for triazolam control doses increased over time, peaking ∼2 hours following dosing at a mean score of 65.0 and 63.4 for triazolam 0.5 mg and 1.0 mg, respectively. Conclusions: Drug-liking following sunobinop at a potential therapeutic dose was not different from placebo and was significantly lower compared with triazolam at a recommended dose. In addition, its good tolerability profile suggests sunobinop may be a useful new treatment option, particularly in at-risk populations.
- Open Access
- 12 August 2025
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 65 (12) , 1661-1675
Reversal of Fentanyl‐Induced Respiratory Depression in Healthy Subjects by Intramuscular Nalmefene Administered by Auto‐Injector Versus Intranasal Naloxone
As illegally made fentanyl and congeners continue to drive overdose deaths in the US, experts have called for stronger and longer‐lasting antagonists. A randomized, 4‐period, 2‐treatment crossover replicate‐design study in healthy moderately‐experienced opioid users (n = 24) evaluated the reversal of opioid‐induced respiratory depression (OIRD) by intramuscular (IM) nalmefene 1.5 mg administered by auto‐injector delivering a formulation developed for faster onset, compared to intranasal (IN) naloxone 4 mg. Fentanyl infusions were administered to induce a 50% reduction in minute ventilation (MV). Reversal of OIRD, pharmacokinetics, and safety were investigated under steady‐state fentanyl agonism. For the primary endpoint, nalmefene demonstrated superiority at 5 min with an MV increase of 4.59 L/min, more than twice the 1.99 L/min increase for naloxone ( P < .0001). Nalmefene superiority was also demonstrated at 10, 15, 20, and 30 min, while non‐inferiority was demonstrated at 2.5 and 90 min. The time‐course of mean antagonist concentrations correlated with increases in mean MV, peaking at approximately 5‐10 min following nalmefene compared to 20‐30 min following naloxone. Decreases in transcutaneous CO 2 (TCO 2 ) followed a similar time‐course with a slight delay. At each threshold of percent reversal (25%‐100%), nalmefene consistently showed a faster time to onset than naloxone. Both antagonist treatments were tolerated with no serious adverse events. This study shows that nalmefene 1.5 mg IM administered by auto‐injector achieved a faster onset, higher magnitude, and longer duration of reversal of OIRD compared to naloxone 4 mg IN and represents another option for the treatment of opioid overdose.
- 12 August 2025
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 65 (12) , 1661-1675
Open AccessReversal of Fentanyl‐Induced Respiratory Depression in Healthy Subjects by Intramuscular Nalmefene Administered by Auto‐Injector Versus Intranasal Naloxone
As illegally made fentanyl and congeners continue to drive overdose deaths in the US, experts have called for stronger and longer‐lasting antagonists. A randomized, 4‐period, 2‐treatment crossover replicate‐design study in healthy moderately‐experienced opioid users (n = 24) evaluated the reversal of opioid‐induced respiratory depression (OIRD) by intramuscular (IM) nalmefene 1.5 mg administered by auto‐injector delivering a formulation developed for faster onset, compared to intranasal (IN) naloxone 4 mg. Fentanyl infusions were administered to induce a 50% reduction in minute ventilation (MV). Reversal of OIRD, pharmacokinetics, and safety were investigated under steady‐state fentanyl agonism. For the primary endpoint, nalmefene demonstrated superiority at 5 min with an MV increase of 4.59 L/min, more than twice the 1.99 L/min increase for naloxone ( P < .0001). Nalmefene superiority was also demonstrated at 10, 15, 20, and 30 min, while non‐inferiority was demonstrated at 2.5 and 90 min. The time‐course of mean antagonist concentrations correlated with increases in mean MV, peaking at approximately 5‐10 min following nalmefene compared to 20‐30 min following naloxone. Decreases in transcutaneous CO 2 (TCO 2 ) followed a similar time‐course with a slight delay. At each threshold of percent reversal (25%‐100%), nalmefene consistently showed a faster time to onset than naloxone. Both antagonist treatments were tolerated with no serious adverse events. This study shows that nalmefene 1.5 mg IM administered by auto‐injector achieved a faster onset, higher magnitude, and longer duration of reversal of OIRD compared to naloxone 4 mg IN and represents another option for the treatment of opioid overdose.
- Open Access
- 30 September 2024
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 65 (2) , 206-216
Time Course of Reversal of Fentanyl‐Induced Respiratory Depression in Healthy Subjects by Intramuscular Nalmefene and Intramuscular and Intranasal Naloxone
The increase in opioid overdose deaths, particularly involving potent, long‐acting synthetic opioids, has led to calls for stronger, longer‐acting opioid‐overdose‐reversal agents. Using an opioid‐induced respiratory depression model, we investigated the onset and time course of action of naloxone and a long‐acting opioid antagonist, nalmefene, in reversing the effects of an ongoing intravenous fentanyl infusion over a period of up to 100 min. Healthy, moderately experienced opioid users received intramuscular (IM) nalmefene 1 mg, IM naloxone 2 mg, or intranasal (IN) naloxone 4 mg after fentanyl‐induced respiratory depression was established based on reduction in respiratory minute volume (MV). Each participant received each opioid antagonist twice per a randomized crossover schedule. Reversal of respiratory depression, pharmacokinetics, and safety were investigated. Participants showed rapid increases in plasma opioid antagonist concentrations, and meaningful reversal of depressed MV tended to occur earlier with IM nalmefene and IM naloxone than with IN naloxone. Compared to naloxone, nalmefene provided extended exposure, and mean MV was maintained at a higher level. All participants experienced treatment‐related adverse events, but none were severe, serious, or led to study drug discontinuation. This study provides evidence that IM nalmefene 1 mg achieves reversal of fentanyl‐induced respiratory depression similar to or better than that achieved with standard‐of‐care naloxone treatments. No new safety concerns were raised for IM nalmefene at the tested dose. The pharmacokinetic and pharmacodynamic properties of IM nalmefene position it as an important treatment option in opioid overdose reversal, particularly given the increasing prevalence of overdoses involving potent, long‐acting synthetic opioids.
- 30 September 2024
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 65 (2) , 206-216
Open AccessTime Course of Reversal of Fentanyl‐Induced Respiratory Depression in Healthy Subjects by Intramuscular Nalmefene and Intramuscular and Intranasal Naloxone
The increase in opioid overdose deaths, particularly involving potent, long‐acting synthetic opioids, has led to calls for stronger, longer‐acting opioid‐overdose‐reversal agents. Using an opioid‐induced respiratory depression model, we investigated the onset and time course of action of naloxone and a long‐acting opioid antagonist, nalmefene, in reversing the effects of an ongoing intravenous fentanyl infusion over a period of up to 100 min. Healthy, moderately experienced opioid users received intramuscular (IM) nalmefene 1 mg, IM naloxone 2 mg, or intranasal (IN) naloxone 4 mg after fentanyl‐induced respiratory depression was established based on reduction in respiratory minute volume (MV). Each participant received each opioid antagonist twice per a randomized crossover schedule. Reversal of respiratory depression, pharmacokinetics, and safety were investigated. Participants showed rapid increases in plasma opioid antagonist concentrations, and meaningful reversal of depressed MV tended to occur earlier with IM nalmefene and IM naloxone than with IN naloxone. Compared to naloxone, nalmefene provided extended exposure, and mean MV was maintained at a higher level. All participants experienced treatment‐related adverse events, but none were severe, serious, or led to study drug discontinuation. This study provides evidence that IM nalmefene 1 mg achieves reversal of fentanyl‐induced respiratory depression similar to or better than that achieved with standard‐of‐care naloxone treatments. No new safety concerns were raised for IM nalmefene at the tested dose. The pharmacokinetic and pharmacodynamic properties of IM nalmefene position it as an important treatment option in opioid overdose reversal, particularly given the increasing prevalence of overdoses involving potent, long‐acting synthetic opioids.
- Open Access
- 2 January 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (1)
The nociceptin/orphanin FQ receptor partial agonist sunobinop promotes non-REM sleep in rodents and patients with insomnia
The potent and partial agonist sunobinop activates the nociceptin/orphanin-FQ peptide receptor and promotes non-REM sleep in rodents and patients with insomnia.
- 2 January 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (1)
Open AccessThe nociceptin/orphanin FQ receptor partial agonist sunobinop promotes non-REM sleep in rodents and patients with insomnia
The potent and partial agonist sunobinop activates the nociceptin/orphanin-FQ peptide receptor and promotes non-REM sleep in rodents and patients with insomnia.